CatalYm

Biotech · Munich, DE

Develops GDF-15-targeting immunotherapies for cancer.

In the network

Shares the most investors with (number = shared investors):

Create a free EquityFlow account to see CatalYm's 1 funding round, 8 investors, 12 similar companies.